Table 1 Population description
ACE cohort | Heidelberg/Mannheim cohort | P-value of difference | |
|---|---|---|---|
MCI patients (N) | 142 | 40 | |
Metabolomics profiling tissue | CSF and Plasma | CSF | |
Age (SD) blood collection, years | 71.95(7.74) | 68.85(8.51) | 0.043 |
Female (%) | 74(52.11%) | 22(55%) | 0.886 |
Body Mass index (SD) | 26.47(3.75) | 25.86(3.62) | 0.354 |
Lipid-lowering medication user (%) | 63(44.37%) | 11(27.5%) | 0.083 |
Amyloid-beta 42 in pg/mL (SD) | 791.59 (337.36) | 690.85 (394.14) | 0.151 |
P-Tau in pg/mL (SD) | 71.37 (37.31) | 63.17 (29.97) | 0.153 |
Total tau in pg/mL (SD) | 425.87 (288.88) | 380.95 (326.98) | 0.435 |
APOE genotype N (%) | |||
APOE ε4 (ε4ε4/ε3ε4/ε2ε4) | 50 (35.21%) | 18 (45%) | 0.344 |
APOE ε3ε3 | 81 (57.04%) | 18 (45%) | 0.242 |
APOE ε2ε2/ε2ε3 | 11 (7.75%) | 4 (10%) | 0.895 |
Amyloid positive | 68 (47.89%) | 22 (55%) | 0.445 |
ATN categories | |||
A-T-N- | 43 (30.28%) | 12 (30%) | 0.873 |
A + T-N- | 19 (13.38%) | 11 (27.5%) | 0.094 |
A + T + N- | 9 (6.34%) | 4 (10%) | 0.757 |
A + T + N + | 40 (28.17%) | 7 (17.5%) | 0.140 |